Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A

In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared with no treatment in patients with hemophilia A with...

RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia

The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A or B with or without inhibitors, leading to improved...

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients...

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer who develop VTE may be at an increased risk...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), was able to be administered safely in patients...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at five years in patients with beta-thalassemia, when the transplant...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results from the U.K. National Cancer Research Institute’s Myeloma XI...

Ropeginterferon Alfa-2B Versus Hydroxyurea in Patients With Polycythemia Vera

Treatment with ropeginterferon alfa-2B, a mono-pegylated proline interferon, reduced JAK2 allele burden in patients with polycythemia vera (PV) and appeared to modify the underlying...

Fostamatinib Improves Platelet Counts in Certain Patients With Heavily Pretreated ITP

In a phase II study published in Blood, the oral SYK inhibitor fostamatinib was safe and effective in a cohort of 16 patients with...

Updated Results From ZUMA-1 Show “Promising” Response Rates With CAR T-Cell Therapy in ...

Treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a high objective response rate (ORR) in patients with relapsed/refractory non-Hodgkin...

Evaluating the Hedgehog Inhibitor Glasdegib in Patients With Heavily Pretreated Myelofibrosis

In a phase Ib/II trial of patients with myelofibrosis whose disease did not respond to JAK inhibitors, treatment with the hedgehog inhibitor glasdegib did...
Advertisement

Current Issue

December 2017, Volume 3, Issue 14

This issue features physicians' insights on gun control, the use of cannabis for symptom relief, and more.